ulcerative colitis
Conditions
Interventions
Control group:Prednisone+Azathioprine/Adalimumab
Test group:Prednisone+Azathioprine/Adalimumab+umbilical cord blood mononuclear cells
Sponsors
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Western medicine diagnosis is consistent with patients with refractory ulcerative colitis; 2. Aged 18 to 65 years, male or female; 3. Those who voluntarily participate in this clinical study and have signed an informed consent .
Exclusion criteria
Exclusion criteria: 1.Patients with non-refractory UC; 2.Those who are pregnant or breastfeeding, or have a childbirth plan in the near future; 3.People with severe allergies or allergies to known ingredients in basic treatments; 4.Patients with severe primary diseases such as severe cardiovascular and cerebrovascular diseases, liver and kidney, and hematopoietic system; 5.There are serious complications, such as local stenosis, intestinal obstruction,intestinal perforation, multiple intestinal polyps, toxic megacolon, rectal cancer, etc.; 6.Patients with mental disorders and intellectual disabilities; 7.Patients who have participated in clinical studies of other drugs in the past 3 months; 8.Those who are seriously ill and need emergency treatment; 9.Patients who are still undergoing other treatment options for ulcerative colitis; 10.Researchers believe that it is not suitable for entry.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical efficacy rate;Clinical response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical symptom score;Endoscopic response rate;Mucosal healing rate;Erythrocyte sedimentation Rate;C-Reactive Proteine; | — |
Countries
China
Contacts
Public ContactJiang Xueliang
The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Outcome results
None listed